{"disease":{"id":"adenocarcinoma-of-lung","name":"adenocarcinoma of lung"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05907577","title":"Early Detection of Lung Cancer With Machine Learning Based on Routine Clinical Investigations","phase":"","overall_status":"UNKNOWN","enrollment_count":7500,"lead_sponsor_name":"The University Clinic of Pulmonary and Allergic Diseases Golnik","has_results":false},{"nct_id":"NCT06441357","title":"Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT05550961","title":"APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT01014286","title":"Lung Cancer Mutation Consortium Protocol","phase":"","overall_status":"COMPLETED","enrollment_count":1100,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT06645743","title":"Retrospective Analysis of Clinical and CT Features to Predict Spread Through Air Space in Stage IA Lung Adenocarcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1100,"lead_sponsor_name":"The Third Affiliated Hospital of Kunming Medical College.","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03676192","title":"To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":689,"lead_sponsor_name":"Celltrion","has_results":true},{"nct_id":"NCT04165759","title":"HRCT in Prediction of Tumor Invasion in GGO Lung Adenocarcinoma (ECTOP-1008)","phase":"","overall_status":"COMPLETED","enrollment_count":620,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05669430","title":"A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":365,"lead_sponsor_name":"GV20 Therapeutics","has_results":false},{"nct_id":"NCT04557449","title":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":362,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07070518","title":"Study of GV20-0251 in Participants With Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"GV20 Therapeutics","has_results":false},{"nct_id":"NCT03059641","title":"Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Geneplus-Beijing Co. Ltd.","has_results":false},{"nct_id":"NCT07277413","title":"A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"IDEAYA Biosciences","has_results":false},{"nct_id":"NCT04566432","title":"Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Geneplus-Beijing Co. Ltd.","has_results":false},{"nct_id":"NCT03838588","title":"The Tracking Molecular Evolution for NSCLC (T-MENC) Study","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Geneplus-Beijing Co. Ltd.","has_results":false},{"nct_id":"NCT02443324","title":"A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01218516","title":"A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Morphotek","has_results":true},{"nct_id":"NCT05252676","title":"Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011)","phase":"","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03184571","title":"Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"BerGenBio ASA","has_results":true},{"nct_id":"NCT04122833","title":"Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study","phase":"","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Konkuk University Medical Center","has_results":false},{"nct_id":"NCT03734913","title":"A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":65,"lead_sponsor_name":"Guangdong Zhongsheng Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04459078","title":"Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":63,"lead_sponsor_name":"Hunan Cancer Hospital","has_results":false},{"nct_id":"NCT05245630","title":"Comparison of Robotic Arm-assisted PET/CT-guided Lung Biopsy With PET Fused CT- Fluoroscopy-guided Lung Biopsy","phase":"","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Post Graduate Institute of Medical Education and Research, Chandigarh","has_results":false},{"nct_id":"NCT04046614","title":"Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT01362790","title":"SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05565677","title":"Prognostic Value of Lung Cancer MicroAnatomy in 3D","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Aristotle University Of Thessaloniki","has_results":false},{"nct_id":"NCT03298763","title":"Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":46,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT01259089","title":"Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT02303977","title":"Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Abramson Cancer Center at Penn Medicine","has_results":true},{"nct_id":"NCT04007744","title":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01345851","title":"Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":29,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT01877083","title":"Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT04770688","title":"Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT04086680","title":"The Detection of EGFR Mutations in Liquid Based Cytology Samples","phase":"","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Royal Cornwall Hospitals Trust","has_results":false},{"nct_id":"NCT03371381","title":"An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT06299163","title":"NM32-2668 in Adult Patients With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Numab Therapeutics AG","has_results":false},{"nct_id":"NCT05194735","title":"Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Alaunos Therapeutics","has_results":true},{"nct_id":"NCT05292859","title":"Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs","phase":"","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Alaunos Therapeutics","has_results":false},{"nct_id":"NCT04027946","title":"LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02650635","title":"TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03041181","title":"Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Nasser Hanna, M.D.","has_results":true}],"total":44},"guidelines":[],"source":"Drug Landscape verified database"}